{"id":"NCT00947297","sponsor":"Amgen","briefTitle":"Study of the Safety of HPN (Hyperion)-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)","officialTitle":"A Phase 3, Open-Label Study of the Safety of HPN-100 for the Long-Term Treatment of Urea Cycle Disorders (Treat UCD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-11","primaryCompletion":"2011-09","completion":"2011-11","firstPosted":"2009-07-28","resultsPosted":"2013-08-15","lastUpdate":"2024-07-10"},"enrollment":60,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Urea Cycle Disorders"],"interventions":[{"type":"DRUG","name":"HPN-100","otherNames":["GT4P, Glyceryl tri-(4-phenylbutyrate)"]}],"arms":[{"label":"HPN-100","type":"EXPERIMENTAL"}],"summary":"This was a long-term safety study HPN-100 in urea cycle disorder (UCD) subjects. Subjects were assessed regularly for safety and control of their venous ammonia. Hyperammonemic events were characterized with respect to contributing factors, such as intercurrent illness, diet, and noncompliance with medication.","primaryOutcome":{"measure":"Rate of Adverse Events (Number of Participants Who Experienced Any AE Considered Related to Study Drug)","timeFrame":"1 year","effectByArm":[{"arm":"HPN-100","deltaMin":33,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":22,"countries":["United States","Canada"]},"refs":{"pmids":["24144944","22961727"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":60},"commonTop":["Vomiting","Upper respiratory tract infection","Nausea","Diarrhoea","Nasopharyngitis"]}}